Biomea Fusion Inc. (NASDAQ:BMEA) is one of the overlooked growth stocks to buy. On January 14, Rodman & Renshaw initiated coverage of Biomea Fusion with a Buy rating and $8 price target.
In Q3 2025, Biomea announced that the company was shifting its strategy to focus on its two primary assets: icovamenib, a menin inhibitor for type 2 diabetes/T2D, and BMF-650, an oral GLP-1 receptor agonist for obesity. Icovamenib is an oral small molecule designed to partially inhibit menin, a protein that acts as a brake on pancreatic beta-cell growth. By inhibiting menin, the therapy aims to regenerate and reactivate healthy, insulin-producing beta cells, potentially offering a disease-modifying treatment for diabetes rather than just managing symptoms.
During the quarter, Biomea Fusion Inc. reported durable 52-week data from its Phase II COVALENT-111 study. In patients with severe insulin-deficient T2D, a short 12-week course of icovamenib resulted in a sustained 1.5% mean reduction in HbA1c nine months after dosing ended. Additionally, patients who had failed to reach glycemic targets on GLP-1 therapies saw a 1.3% reduction in HbA1c. These results are particularly notable because they suggest a legacy effect where benefits continue long after the medication is stopped.
Biomea Fusion Inc. is a clinical-stage diabetes and obesity medicines company that discovers and develops oral covalent small molecule drugs to treat patients with metabolic diseases in the US.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
This article is originally published at Insider Monkey.
